Summary from GEO: "Many cancers carry recurrent change-of-function mutations in RNA splicing factor genes, which induce sequence-specific changes in RNA splicing. Here, we describe a method to harness this change in RNA splicing activity to drive splicing factor mutation-dependent gene expression in cancers and selectively eliminate these tumors. We engineered synthetic introns which were efficiently...

Description from PRIDE: "Minor intron-containing genes (MIGs) are crucial cell cycle regulators and are essential for cell survival. Thus, we explored whether MIGs play a role in cancer progression and cancer therapy resistance. Here we show that MIG-expression segregates sensitive and resistant prostate cancer cells from each other and them from benign tissue. Moreover, the rate of minor intron...

Description from Mendeley Data: "Men with androgen receptor-negative castration-resistant prostate cancer (ARN CRPC) do not benefit from androgen receptor-directed therapies, face low survival rates, and have few alternative therapeutic options. Addressing this unmet clinical need requires new approaches to identify this more aggressive form of disease early on and to treat it effectively. A recent...